Targovax R&D Day: New York - October 11, 2018

New York, October 11, 2018

PLEASE JOIN US FOR A KOL EVENT

Leading experts discuss the oncolytic virus landscape and present interim data from Targovax’s ongoing melanoma and mesothelioma trials

 

 

General Agenda

11:30AM-12:00PM
Registration & Lunch

12:00-12:10PM
Welcome Remarks
Øystein Soug, CEO, Targovax

12:10-12:50PM
Oncolytic Virus Overview and Q&A
Dmitriy Zamarin, MD, PhD

12:50-1:30PM
Melanoma: the disease, CPIs, and lack of treatment options; Early ONCOS-102 data
Alexander N. Shoushtari, MD

1:30-1:50PM
Mesothelioma ORR Data
Magnus Jaderberg, CMO, Targovax

1:50-2:00PM
Closing Remarks
Øystein Soug, CEO, Targovax

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Targovax [TRVX:OS] NKr428 MM MCap
Tar­go­v­ax is a clin­i­cal stage biotech­nol­o­gy com­pany de­vel­op­ing im­mune ac­ti­va­tors to tar­get hard-to-treat solid tu­mors. Tar­go­v­ax’s lead prod­uct can­di­date, ON­COS-102, is a ge­net­i­cal­ly mod­i­fied on­co­lyt­ic ade­n­ovirus that has been en­gi­neered to se­lec­tive­ly in­fect and re­pli­cate in can­cer cells. It has been shown to ac­ti­vate the im­mune sys­tem to gen­er­ate tu­mor-spe­cif­ic im­mune re­spons­es. [more in­for­ma­tion]

Location of the Event and Other Places